Version 1.0.3

Submission
Home > Submission

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/07/2018
Deadline Date	30/07/2018
Date Submitted	20/07/2018
Туре	Performance In Delivering
NHS provider	Maidstone and Tunbridge Wells NHS Trust

Showing records 1 to 6 of 6. Pages: 1

30250	30249	30008	30007	30006	30005	Id
30250 16/EM/0332 205699	30249 14/YH/1056 147421	30008 16/YH/0154 202759	30007 16/EE/0463 214371	30006 16/LO/1717 212505	30005 16/EM/0165 203281	Research Ethics Committee Reference Number
205699	147421	202759	214371	212505	203281	Integrated Research Application System Number
MAXIMISE: Managing axial manifestations in psorratic arthritis with secukinaumab, a randomised double-blind, placebocontrolled, multicentre, 52 week study to assess the efficacy and safety of Secukinumab 150mg or 300mg s.c. in patients with active p	AB 10004 Study- A Multicenter, Randomised, Open-label, three- parallel groups, phase 2-3 study to evuate the effiency and safety of masitinib with dexamenthasone, gemcitabine with dexamethasone and the combination of mastinib, gemcitabine and dexametha	DOMPERIDONE JNJ-17296812: A multicenter, double-blind, randomised, Placebo-controlled, parallel-group, Prospective Study to Evaluate the Safety and Efficiency of Domperidone in 6 Agreed Womiting du	CompLEEment-1 An open-label multicentre phase IIIb study to assess the safety and efficacy of ribocicilib (LEE011) in combination with letrozole for the treatment ofmen and postmenopausal women with hormone receptorship (HR+) HER2-negative (HER2-) ad	ACE-CL-309 A randomised, multicentre, open-label, phase 3 study of Acalabrutinib (ACP-196) versus Investigator's choice of either Idelalisib plus Rituximab or Bendamustine plus Rituximab in subjects with relapsed or refactory chomic lymphocytic leuk	ARIAD AP26113-13-301 A phase 3 multicentre open-label study of Brigatinib (AP26113) versus Crizotinib in patients with ALK-positive advanced lung cancer	Integrated Research Application Name of Trial System Number
Number Agreed	Number Agreed	Number Agreed	Number Agreed	Number Agreed	Number Agreed	Target Number Of Patients Agreed?
4	4	G)	ō	ω	2	
4	4	O1	6	3	2	Minimum Number Maximum Number Of Patients Agreed Of Patients Agreed (Enter Same In Both If Only One Number) Mumber) Maximum Number (Enter Same In Both If Only One Number)
Not Available / Not Agreed	Date Agreed	Date Agreed	Date Agreed	Date Agreed	Date Agreed	Target Date To Recruit Patients Agreed?
	06/06/2017 1	30/04/2018	01/12/2019	28/02/2018 0	22/03/2017 0	Agreed to recruit target number of patients
	-3	1	55	0	0	Total Number Of Patients Recruited At The Agreed Target Date
28/03/2018	28/02/2018	26/07/2017	31/10/2017	15/12/2017	28/07/2017	Date That The Trial Closed To Recruitment
4	7	1	УI	0	7	Total Number Of Study Participants Recruited
Recruitment Finished	Withdrawn By Sponsor	Withdrawn By Sponsor	Recruitment Finished	Withdrawn By Sponsor	Recruitment Finished	Total Number Of For Study Participants Recruited Recruited Reason For Closure Of
	Withdrawn By Sponsor closed as study futile	Sponsors closed due to pre- specified futility criteria which is unlikely that a statistically By Sponsor significant difference in the prima endpoint can be achieved by enrolling additional pts		Withdrawn Site closed by sponsor due to lac		Comments

Showing records 1 to 6 of 6. Pages: 1